AN2 Therapeutics Inc

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RF Acquisition Corp

The IPO market stayed relatively quiet, with only one IPO and one SPAC pricing this past week. Pipeline activity maintained its slow pace, with only two small IPOs and one SPAC submitting initial filings.

U.S. IPO Weekly Recap: The IPO Market Remains Frozen In A 1 IPO Week

AN2 Therapeutics Inc (NASDAQ: ANTX) will be offering 4.6 million shares at $15 a share in its initial public offering, under the ticker 'ANTX,' raising $69 million.  The Company announced IPO plans earlier this month.

RA Capital-Backed AN2 Therapeutics Hits NASDAQ, With IPO Price At $15

Biotech AN2 Therapeutics sold 4.6 million shares at $15 each, the mid-point of its $14 to $16 range. It's the second conventional IPO this month.

AN2 Therapeutics Stock to List Today

MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the pricing of its upsized initial public offering of 4,600,000 shares of its common stock at a price to the public of $15.00 per share. All of the shares of common stock are being offered by AN2 Therapeutics. The gross proceeds to AN2 Therapeutics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by AN2 Therapeutics, are expected to be $69.0 million. In addition, AN2 Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 690,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

AN2 Therapeutics Announces Pricing of Upsized Initial Public Offering

AN2 Therapeutics has filed proposed terms for a $60 million IPO.

IPO Update: AN2 Therapeutics Seeks $60 Million U.S. IPO

Biotech AN2 Therapeutics will be the second company to go public through a traditional initial public offering in March.

AN2 Therapeutics Set for a March IPO

News for AN2 Therapeutics Inc Stock (ANTX)